שימוש בדיפירידאמול מגן על עובדי מערך הרפואה מהידבקות בקורונה.
Тромбоз, гемостаз и реология
Publication Date: דצמבר 8, 2020
Peer Reviewed: Yes
Publication Type: Original | Clinical Prospective
The opportunity of dipyridamole using for nonspecific primary prophylaxis against the COVID‐19 infection in healthcare staff
Summary. Background. Healthcare workers are under high risk of the novel coronavirus infection COVID‐19. Objectives: to show the opportunity of dipyridamole using within the set of primary prophylaxis measures against the infection of COVID‐19. Patients/Methods. We followed up 33 people from medical staff, of them 14 were taking dipyridamole in addition to standard prophylaxis methods; the comparison group consisted of 19 people who did not take dipyridamole. Results. Despite standard prophylaxis in a multidisciplinary hospital, out of 14 staff members who took dipyridamole, 5 (35.7%) catch coronavirus infection COVID‐19 (justified); interstitial pneumonia was diagnosed in 4 people. In a group of 19 employees who did not take dipyridamole, 13 (68.4%) fell ill; interstitial pneumonia was diagnosed in 11 people. Conclusions. The opportunity of dipyridamole using has been shown as an additional means to reduce the risk to infect with COVID‐19.